CardioVascular Health Endpoints and Real-world data Tutorial (CV-HEART)
The CardioVascular Health Endpoints and Real-world data Tutorial (CV-HEART) tool is a web-based eLearning application developed to enhance your understanding of clinical research and real-world evidence pertaining to anticoagulation treatment and to provide important points to consider when interpreting study design, endpoints, and methodologies. This application provides a didactic overview of three chapters: Chapter 1 discusses study design for anticoagulation treatment; Chapter 2 discusses common endpoints used in clinical studies of anticoagulation treatment; and lastly Chapter 3 discusses some methodological considerations in clinical studies. The module concludes with a checklist, which can be used as a reference when evaluating published clinical studies.
Tool access form
Thank you for choosing this program. Information you provide may be shared by Janssen Scientific Affairs, LLC, with affiliates and third parties involved for the fulfillment of requests. Any information you provide will be governed by our Privacy Policy. By completing this form and clicking the below "Confirm" button, you have read, understand, and agree to these conditions.
Terms and conditions
This software, documentation, and any CardioVascular Health Endpoints and Real-world data Tutorial (CV-HEART) supplemental information distributed by Janssen Pharmaceuticals, Inc. are protected under the copyright laws of the United States of America and under international copyright conventions. No part of this product may be reproduced or transmitted in any form or by any means, electronic or mechanical, for any purpose, without the express written permission of Janssen Pharmaceuticals, Inc. All rights are expressly reserved.
Janssen Pharmaceuticals, Inc. is providing CV-HEART on an "as-is" basis and hereby disclaims all warranties, whether expressed or implied, including any warranty as to the quality, merchantability, or noninfringement of this software for any purpose. Janssen Pharmaceuticals, Inc. does not warrant that CV-HEART will operate on an uninterrupted or error-free basis. Janssen Pharmaceuticals, Inc. shall in no way be liable for any loss or corruption of data or information on account of the use or unavailability of any copy of CV-HEART, including loss or corruption of user's existing software and/or data. Information in this document is subject to change without notice.
In no event will Janssen Pharmaceuticals, Inc. be liable for any damages, including lost revenues, profits, data, or other information, or for any special, indirect, incidental, consequential, or punitive damages arising out of the use of or the inability to use CV-HEART, even if Janssen Pharmaceuticals, INC. has been advised of the possibility of such damages.
Only "Authorized Personnel" authorized by Janssen Pharmaceuticals, Inc. may have access to and the right to use this software. "Authorized Personnel" includes only employees of healthcare organizations who were provided with access to the software by a Janssen Pharmaceuticals, Inc. representative. If you do not qualify as "Authorized Personnel," you should exit this program immediately.
If you qualify as "Authorized Personnel," you should be aware that:
1. Janssen Pharmaceuticals, Inc. is providing you with CV-HEART only as a tool to help you to better understand and interpret study designs and outcomes of clinical research and real-world evidence pertaining to anticoagulation treatment. Payors, Physicians and other healthcare professionals (HCPs) retain full responsibility for all clinical decisions relating to individual patient treatment and care.
2. UNDER NO CIRCUMSTANCES should CV-HEART be used as a substitute or replacement for medical diagnosis or clinical decisions or treatment recommendations.
3. CV-HEART is not intended to be and should not be used as all-inclusive or necessarily complete for any purpose, and there may be omissions, typographical and other errors, conflicting information, or inaccuracies in CV-HEART.
4. CV-HEART is not intended to make any comparative efficacy or safety claims between anticoagulation treatments.
CV-HEART and associated logo and artwork are trademarks of Janssen Pharmaceuticals, Inc.
Copyright 2021 Janssen Pharmaceuticals, Inc. This material is the sole and exclusive property of Janssen Pharmaceuticals, Inc. (except as otherwise noted) and may not be reproduced, distributed, modified, transmitted, reused, or reposted without the express written permission of Janssen Pharmaceuticals, Inc. All Rights Reserved.